A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.

doi:10.1016/s1091-255x(98)80101-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract - 1 Jan 2000

Iseki H, Ko T C, Xue X Y, Seapan A, Townsend C M

Abstract excerpt

Pancreatic cancers frequently carry mutations in the K-ras, p53, and p16 genes, which regulate cell proliferation. Transition from G1 to S phase of the cell cycle requires activation of cyclin-dependent kinase 2 (Cdk2) which is inhibited by olomoucine and roscovitine. The purpose of this study wa...

Topics

Adenocarcinoma
Antineoplastic Agents
CDC2-CDC28 Kinases
Cell Count
Cell Division
Cyclin-Dependent Kinase 2
Cyclin-Dependent Kinases
DNA, Neoplasm
Dose-Response Relationship, Drug
Enzyme Activation
Enzyme Inhibitors
Flow Cytometry
G1 Phase
Genes, p16
Genes, p53
Genes, ras
Growth Inhibitors
Histones

Source

Open in PubMed

Identifiers

PMID: 9841966
DOI: 10.1016/s1091-255x(98)80101-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9841966-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics